Future research in MRD is focused on improving the sensitivity and specificity of detection methods. The integration of liquid biopsy techniques, which analyze circulating tumor DNA (ctDNA) in blood samples, holds promise for non-invasive MRD monitoring. Advances in single-cell sequencing and artificial intelligence are also expected to enhance our ability to detect and characterize residual disease more accurately.
